A Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel

About this Study

The purpose of this research study is to learn about the effects of the study drug Docetaxel, when given in combination with radiation therapy and hormone suppression therapy versus when using radiation and hormone suppression therapy alone in men with a high chance of prostate cancer recurrence after surgically removing the prostate.

Sponsor Protocol ID:NRG-GU002
IRB Number:2018-0146
Actively Enrolling
Interventional
Phase 2
May 28, 2019
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No

Inclusion Criteria
  • Prior androgen deprivation therapy. 
  • The patient or a legally authorized representative must provide study-specific informed consent prior to Step 1 registration. 
  • Age ≥ 18

Exclusion Criteria

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:Henegan, John C, M.D.
How to participate in our Clinical Trials